期刊文献+

胃癌的靶向治疗 被引量:1

下载PDF
导出
摘要 胃癌在世界范围内占恶性肿瘤死因的第二位,年发病人数近百万,死亡人数近80万.在我国,胃癌发病和死亡人数均约占世界一半左右,据估计就诊患者中约80%-90%为中晚期,5年生存率20%左右。目前胃癌临床治疗上,随着外科治疗的逐渐规范,通过单纯外科手术提高患者生存已近极限。化疗药物作为传统治疗肿瘤的重要手段,通过针对细胞的毒性发挥作用,对生存有一定的改善,但存在明确的副作用。靶向药物是近些年新兴的,主要针对肿瘤特定的生物学标志物发挥作用,具有针对性,特定患者反应率高,毒副作用小。靶向治疗是近几年研究的重点,而且有逐年增加的趋势。
作者 季加孚 季鑫
出处 《临床外科杂志》 2013年第10期753-755,共3页 Journal of Clinical Surgery
关键词 胃癌 靶向治疗
  • 相关文献

参考文献19

  • 1Jemal AF,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61 (2):69-90. 被引量:1
  • 2Matory YL,Burt M.Esophagogastrectomy:reoperation for complications[J].J Surg Oncol,1993,54(1):29-33. 被引量:1
  • 3Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376 (9742):687-697. 被引量:1
  • 4Ohtsu A,Shah MA,Van Cutsem E,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:arandomized,double-blind,placebo-controlled phase Ⅲ study[J].J Clin Oncol,2011,29 (30):3968-3976. 被引量:1
  • 5Wainberg ZA,Anghel A,Desai AJ,et al.Lapatinib,a dual EGFR and HER2 kinase inhibitor,selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo[J].Clin Cancer Res,2010,16(5):1509-1519. 被引量:1
  • 6Pinto C,Di Fabio,Siena S,et al.Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)[J].Ann Oncol,2007,18 (3):510-517. 被引量:1
  • 7Han SW,Oh DY,Im SA,et al.Phase Ⅱ study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J].Br J Cancer,2009,100(2):298-304. 被引量:1
  • 8Dragovich T,McCoy S,Fenoglio-Preiser CM,et al.Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127[J].J Clin Oncol,2006,24 (30):4922-4927. 被引量:1
  • 9Rojo F,Tabernero J,Albanell J,et al.Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma[J].J Clin Onco1,2006,24 (26):4309-4316. 被引量:1
  • 10Arteaga C.Targeting HER1/EGFR:a molecular approach to cancer therapy[J].Semin Oncol,2003,30(3 Suppl 7):3-14. 被引量:1

同被引文献9

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部